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Introduction
The mammary gland is very sensitive to radiation-
associated carcinogenesis, especially after exposures at
young ages. Many aspects of the association between
radiation and breast cancer have been elucidated in the
past decades. This review is intended to summarize widely
recognized features of radiation-associated breast cancer
and to add a more detailed overview of relevant recent
findings, especially focusing on factors that modify the
radiation-related risk.
Epidemiology of breast cancer
In 2000, breast cancer was the most common malignant
disease in women worldwide, with an estimated 1.05
million cases. Owing to high levels of screening in
developed countries and the relatively favorable prognosis
of early-stage disease, it is also the most prevalent
malignancy in women, with almost 4 million women alive
who have had breast cancer in the past 5 years [1]. In the
USA, it is estimated that about 216,000 women will be
diagnosed with breast cancer in 2004 and that 40,000
will die from the disease [2]. Male breast cancer is a rare
disease, with an incidence about 1/100 of that for female
breast cancer [2].
Breast cancer is very rare before age 30 years, after which
incidence rises steeply with advancing age up to about
age 50 years. Thereafter, incidence still increases with
age, but more slowly [3]. The strong dependence on age,
as seen for many other adult-type cancers, is probably
related to accumulating genetic damage that occurs
during a human lifespan. The apparent change in slope of
the age–incidence curve at about age 50 years is unique
for breast cancer, and this is presumably related to
hormonal changes associated with menopause, which is
accompanied by a decrease in circulating estrogen levels
[3]. Estrogens and other hormones are thought to affect
the progression of initiated mammary gland cells in the
path to malignancy. This has been shown clearly in early
rodent studies, where chemical-associated or radiation-
associated mammary tumors were most abundant after
additional hormonal stimulation [4]. Post-menopausal
women might therefore experience less tumor progression
than premenopausal women. This concept of hormonal
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Abstract
This paper summarizes current knowledge on ionizing radiation-associated breast cancer in the context
of established breast cancer risk factors, the radiation dose–response relationship, and modifiers of
dose response, taking into account epidemiological studies and animal experiments. Available
epidemiological data support a linear dose–response relationship down to doses as low as about
100 mSv. However, the magnitude of risk per unit dose depends strongly on when radiation exposure
occurs: exposure before the age of 20 years carries the greatest risk. Other characteristics that may
influence the magnitude of dose-specific risk include attained age (that is, age at observation for risk),
age at first full-term birth, parity, and possibly a history of benign breast disease, exposure to radiation
while pregnant, and genetic factors.
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carcinogenesis is also consistent with epidemiological
observations that late menarche and early menopause
have a protective effect against breast cancer. Women
who have a late menarche and/or early menopause have a
smaller number of menstrual cycles and therefore shorter
exposure to ovarian hormones during the reproductive
years than women who have early menarche and/or late
menopause [5,6].
Parity and an early first full-term pregnancy (FFTP) both
have been shown to decrease the long-term breast cancer
risk. Before pregnancy, mammary gland cells are in a
vulnerable undifferentiated state but differentiate to
functioning milk-producing structures during pregnancy. It
is thought that pregnancies, and FFTP in particular,
consecutively decrease the pool of vulnerable breast cells
[7]. Interestingly, young women are at increased risk for
breast cancer in the 5 years post-partum, possibly related
to the promoting effects of the hormonal milieu of
pregnancy [8,9]. The short-term increased risk for breast
cancer was highest for women delivering a first child at
older ages, who might have accumulated more
premalignant conditions than younger women. This dual-
effect phenomenon, namely the short-term increasing, but
long-term reducing, effects of pregnancy on breast cancer
risk, has been shown not only for a first pregnancy but
also for subsequent pregnancies [9]. In addition, the
breast cancer risk for women with FFTP in the age range
30–34 years approaches that of nulliparous women,
whereas those delivering their firstborn after age 35 years
are at higher risk than nulliparous women [5].
The postulated role of hormones in mammary carcino-
genesis was corroborated by studies showing dose-
dependent increasing risks associated with increasing
levels of endogenous sex hormone levels in blood [10].
Exogenous hormones such as oral contraceptives [11]
and post-menopausal hormone replacement therapy [12]
also have been linked to increased breast cancer risk. An
international pooled analysis showed that breast cancer
risk was increased, by 20%, for women who used oral
contraceptives up to breast cancer diagnosis, but not for
women who stopped using oral contraceptives more than
10 years before cancer diagnosis [11]. Other risk factors
for breast cancer include a history of certain types of
benign breast disease (BBD) [13], mammographically
dense tissue [14], high body mass index among post-
menopausal women, height, and alcohol use [15]. Also
implicated are exposures in utero and during childhood to
estrogens and other hormones [15–18], as well as insulin,
insulin-like growth factor-I, and other indicators of energy
balance and growth [15,18]. However, the mechanistic
details remain to be elucidated.
Family history of breast cancer has long been recognized
as another breast cancer risk factor and has been
evaluated by meta-analysis of published data and analysis
of pooled individual-level data [19,20]. Breast cancer risk
increases with the number of affected first-degree
relatives. Risk also seems to be greater for women with a
first-degree relative diagnosed with breast cancer at a
young age (usually defined as less than 50 years). Highly
penetrant mutations in the heritable breast cancer
susceptibility genes, BRCA1 and  BRCA2, account for
some of the relationship between family history and breast
cancer risk, whereas other inherited genetic traits, habits,
and shared environment are also likely contributors. Using
a database of almost 45,000 twins, Lichtenstein and
colleagues estimated that 27% of all breast cancer can be
explained by genetic factors or their interaction with
environmental factors [21], although inherited
susceptibility mutations in BCRA1 and BRCA2 seem to
account for less than 10% of all breast cancer cases
(irrespective of family history) [22,23]. BRCA1 mutations
have been suggested to account for about 45% of breast
cancer cases with a family history of breast cancer [24].
BRCA1 mutations, which seem to be more prevalent than
BRCA2 mutations, probably account for a greater share of
breast cancer cases [24]. Although the roles of these
genes remain to be elucidated, loss of function in both
alleles seems to be necessary for the characteristic
increased risk of early-onset breast cancer [25].
Radiation exposure as a breast cancer risk factor
The accumulated knowledge about radiation-related breast
cancer risk in women derives mainly from epidemiological
studies of patients exposed to diagnostic or therapeutic
medical radiation and of the Japanese atomic bomb
survivors. Table 1 provides selected examples of studies,
many of which include estimated radiation doses to the
breast tissue. More detailed summaries can be found in
Annex I of the most recent UNSCEAR expert report on
effects of ionizing radiation [26].
Medically exposed populations include (1) patients with
scoliosis or tuberculosis monitored by X-ray or fluoro-
scopic examination for treatment efficacy and disease
progress [27–29], (2) patients given radiotherapy for
benign disorders as infants or children [30–32], (3)
women of childbearing age treated with X-rays for BBD
and acute post-partum mastitis [33,34], (4) childhood
cancer survivors, exposed to often high-dose chest
radiation at early ages [35–38], and (5) survivors of adult
cancers treated with radiotherapy [39,40]. The average
estimated radiation dose to the breast tissue varied
considerably across these populations, ranging from
0.02 Sv [32] to more than 20 Sv [41]. (The gray [Gy] is
the unit of absorbed radiation dose. The sievert [Sv] is a
weighted sum of doses [dose equivalent] used for
different types of radiation such as the mixed gamma and
neutron radiation from the atomic bombings. In terms of
biological effectiveness, 1 Sv of mixed radiation is23
assumed to be equivalent to 1 Gy of gamma rays or X-
rays. For most X-rays or gamma rays that are used for
medical purposes, dose in Gy and dose equivalent in Sv
are numerically the same, and in the present report the
dose in Gy will be treated interchangeably with the dose
equivalent in Sv.) In contrast to most other studies, the
overall risk of breast cancer was not clearly elevated in the
tinea capitis cohort [32], which had the lowest average
breast dose. It has been noted that increased breast
cancer risk in a few subgroups of that cohort seemed to
be related to unusually low risk in the control group [42].
Survivors of childhood and adolescent cancer who had
had radiotherapy involving the chest are on the high end of
the dose spectrum [36,41].
Finally, the Life Span Study (LSS) of Japanese atomic
bomb survivors, including 70,165 women, provides
detailed risk estimates on radiation-associated breast
cancer risk and covers a wide range of mixed gamma and
neutron radiation levels, with neutron-weighted doses
(neutron weight = 10) ranging from 0 to more than 5 Sv
and a natural distribution of exposure ages [43].
Quantitative dose–response relationship
Currently available epidemiological data are consistent
with a so-called ‘linear, no-threshold model’ in which the
excess risk of breast cancer is proportional to radiation
dose [26,43,44]. Studies on cellular radiosensitivity have
shown that cells will be killed at high radiation doses and
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Table 1
A selection of epidemiological studies on populations of women exposed to radiation from the atomic bombings or for medical
purposes
No. of women No. of breast cancers
Breast Exposure 
Non- Non- dose age  ERR  at 
Cohort Exposed exposed Exposed exposed (Sv)b (years)b 1 Svg
Atomic bombings
Life Span Study, Japan [43] 70,165 c 1059 – 0.28 27 1.74
Diagnostic radiation
Tuberculosis fluoroscopy, Canada [27]a 31,917 c 319 332 0.89 26 0.90
Tuberculosis fluoroscopy, USA [28] 2573 2367 147 87 0.79 26 0.40
Scoliosis, USA [29]a 4929 644 70 7 0.11 10 5.4
Radiotherapy for benign disorders
Enlarged thymus, USA [30] 1201 2469 22 12 0.69 <1 2.39
Skin hemangioma, Sweden [31] 17,202 c 245 – 0.29 0.5 0.35
Tinea Capitis, Israel [32] 5400 8100 25 27 0.02 7 –
Benign breast disease, Sweden [33] 1216 1874 198 101 5.8 40 0.35
Post-partum mastitis, USA [34] 601 1239 56 59 3.8 28 0.43
No. of cancer survivors Observed Expected RR/OE
Cancer survivors
Pediatric HL (age < 16) LESG, USA [35]d 480 29 0.7 f 11.7 55.5
Childhood cancer, CCSS, USA [36]d 6304 60 3.7 f 7.8 24.7h
Pediatric HL international [37] 2737 52 3.7 f 16 14.1
HL, UK [38]d 2085 19 13.5 f – 2.5h
Breast cancer, Denmark [39]e 56,540 529e – 2.5 51 1.04
Breast cancer, USA [40]e 41,109 655e – 2.8 52 1.33
CCSS, Childhood Cancer Survivor Study; ERR, excess relative risk; expected, expected number of cases; HL, Hodgkin lymphoma; LESG, Late
Effects Study Group; observed, observed number of cases; OE, observed/expected ratio; RR, relative risk. aOutcome breast cancer mortality.
bAverage. cIncluded in the exposed group. dIn the total cohorts 70–90% of patients were treated with radiotherapy. eNested case-control studies
among patients with a first breast cancer and matched controls. fSpecific dose estimates were not reported in these studies, but HL patients can
be exposed to doses of 40 Gy or more [41]. gSource: UNSCEAR 2000 report [26], which also has more detailed descriptions of the individual
studies. hFor the subgroup of patients treated with chest radiotherapy.24
therefore cannot develop into a tumor. In a pooled analysis
of eight studies among female populations exposed to
diagnostic or therapeutic radiation for benign conditions,
or exposed to the atomic bombs in Japan, there was
suggestive evidence of this cell-killing effect in the form of
a flattening of the linear dose–response relationship at the
highest doses [45]. However, a recent large study among
survivors of Hodgkin lymphoma (HL) did not show clear
evidence of such flattening, although these patients
generally are exposed to very high chest doses [46]. A
minimal latency period of 10–12 years is generally
accepted [43,45].
The association is often expressed as excess relative risk
(ERR) per unit of radiation dose in Sv, corresponding to
the mathematical model in which risk = β0(1 + β1 × dose),
where  β0 represents the underlying population risk for
breast cancer and β1 represents ERR per unit dose. The
dose-specific ERR is the relative risk minus 1, or,
equivalently, the excess rate divided by the baseline rate.
For breast cancer, estimated ERR per Sv varies widely
[26]. The risk also can be expressed in terms of excess
absolute risk (EAR), expressed in incident cases per 104
woman-year-Sv, or the annual number of breast cancers
attributable to a radiation exposure of 1 Sv among 10,000
radiation-exposed women. In a pooled analysis of data
from different exposed populations, estimated EAR was
consistent between Japanese atomic bomb survivors and
US populations exposed to diagnostic radiation during
lung collapse therapy for tuberculosis, or to X-ray therapy
for enlarged thymus (pooled estimate 9.9, 95%
confidence interval 7.1–14). However, EAR was
substantially higher for Swedish (32, 21–47) and US (15,
7.7–24) women given radiation therapy for BBD and
substantially lower for two populations of Swedish women
treated as infants with X-rays and radium plaques for
hemangioma (pooled estimate 5.1, 1.3–11, for exposure
at 6 months of age) [45]. The authors noted that BBD is a
poorly defined entity, possibly affecting baseline breast
cancer risk [45].
In addition, dose-specific EAR was similar between atomic
bomb survivors with a single, acute exposure and
Massachusetts tuberculosis fluoroscopy patients with
highly fractionated exposures, but acute exposures in
infancy for treatment of thymic enlargement yielded risks
sixfold higher than those for Swedish patients treated in
infancy with protracted exposures yielding cumulative
doses of 0.02–0.1 Gy to the site of future breast
development. The implications of these findings for
modification of dose-specific breast cancer risk by
fractionation and protraction of dose are unclear, and the
results could reflect effects of yet unrecognized
confounding factors [45]. There therefore seems to be no
simple way to describe the association between radiation
dose and breast cancer incidence, which varies
considerably for different populations. The variation may
be due in part to differences in several factors that can
modify the radiation-related risk (or dose response), as
discussed below.
Modification of dose response
Age at radiation exposure
Women younger than age 20 years at exposure are at
higher risk of radiation-associated breast cancer than
those exposed at older ages. Women more than 50 years
of age old at exposure have no measurably increased risk
of breast cancer [45]. Biologically, age is a surrogate of
various stages in breast tissue development as well as a
marker of cumulative endogenous hormone exposures,
both of which vary considerably across a woman’s
lifespan. In terms of tissue development, the normal breast
is different from many other organs in that it is not fully
differentiated in newborns, despite rapid proliferation and
development  in utero. After a relatively quiet quiescent
period in childhood, rapid proliferation and growth again
take place during puberty followed by terminal endbud
differentiation during a FFTP when the breast is prepared
for lactation [47]. Periods of enhanced cell proliferation,
namely  in utero, puberty and pregnancy, have been
proposed to represent windows of increased
susceptibility for mammary carcinogenesis [48,49].
Proliferation is associated with increased levels of DNA
synthesis, which in turn provides opportunities for DNA
damage by mammary carcinogens and an increased
probability of reproduction of unrepaired or misrepaired
DNA damage to the progeny of the damaged cell [44].
Fetal exposure
Of the three periods during which rapid changes occur in
breast tissue, there are few epidemiological data on the
risk associated with fetal radiation exposure. So far, one
fatal breast cancer has been reported among 1668
females who were in utero during the atomic bomb
explosions in 1945 [50].
Childhood and puberty
With regard to puberty, earlier epidemiological studies
with short follow-up, or studies with partial coverage of
potential age-windows of exposure, have repeatedly found
the second decade of life to represent the most sensitive
window in terms of susceptibility to radiation-associated
breast cancer [51,52]. More recent epidemiological data
suggest that exposures occurring well before puberty
might confer equally elevated risks for radiation-associated
breast cancer, as detailed below.
Childhood cancer survivors provide useful data on
radiation-associated breast cancer (Table 1), in particular
female HL patients who received high-dose radiotherapy
to the chest. Until recently, there was little opportunity to
compare the effects on breast cancer risk of radiation
Breast Cancer Research    Vol 7 No 1 Ronckers et al.25
exposures that took place during the first versus the
second decade of life for two reasons. First, long-term
follow-up studies are needed before the youngest HL
patients reach the ages at which breast cancers are
normally observed with any frequency. Second, HL is rare
in young children; the annual incidence in 5–9-year-olds is
only 10% of that in 15–19-year-olds [53]. Only a few
[36,37,51,52,54] childhood cancer survivor cohort
studies reported on second cancers among subjects
younger than 10 years at diagnosis. Among patients
treated at the youngest ages, breast cancer cases occurred
in the Late Effects Study Group [35] and Childhood Cancer
Survivor Study [36,54] cohorts. Most recent analyses from
these cohorts used appropriate statistical methods to take
into account the underlying increasing risk with increasing
age [55] and showed no statistically significant difference in
breast cancer risk between those diagnosed with HL in
childhood or during puberty or early adolescence
[35,36,54]. Many other reports on HL survivors showed
very high risks of breast cancer among patients diagnosed
before age 15 years [56–59].
Two other recent epidemiological studies provide
evidence that there is an increased risk of breast cancer
for all women exposed to radiation before age 20 years,
namely the atomic bomb survivor studies [43] and the
Canadian Fluoroscopy cohort study [27]. Early LSS
analyses for risk of breast cancer among atomic bomb
survivors were not informative with regard to risk among
women exposed as children because this subgroup had
not been observed at ages of increasing breast cancer
incidence owing to insufficient follow-up, as recognized by
the authors [60,61]. From the early 1980s onwards,
increased breast cancer risk among those younger than
10 years of age at exposure was found in all reports
[43,62,63], the most recent of which showed the following
ERR/Sv by age at exposure: 0–4 years, 3.94; 5–14 years,
2.77; 15–19 years, 2.65; 20–39 years, 1.33 [43].
Pregnancy
Pregnancy represents a third window of rapid changes in
the female breast tissue. In contrast to the period in utero
and during puberty, age cannot be used as a surrogate
measure to define this potentially susceptible period.
Human data on breast cancer risk after irradiation of
pregnant women are sparse. A small study suggests a
high risk of radiation-associated breast cancer (six cases)
among 37 HL patients who had radiotherapy while
pregnant [64]. An earlier study of 1764 female
tuberculosis patients showed that, among all patients
exposed to radiation, the highest rate of breast cancer
incidence per unit radiation dose occurred among 20
pregnant tuberculosis patients, among whom there were
two breast cancers [65]. Although these results are
suggestive of an effect, the numbers of cases are too
small to provide convincing evidence.
Animal studies
Animal models, in particular rats, have been used to
address the potential effects of exposure age or breast
tissue age on chemical-associated or radiation-associated
carcinogenesis [4], because their lifespan
(100–150 weeks) is relatively short and because they
develop mammary tumors. However, the tendency to
develop natural or radiation-related fibroadenoma and/or
adenocarcinoma varies greatly by strain [66,67]. After
exposure to radiation, rats were treated with tumor-
promoting hormones (diethylstilbestrol or estrogen) to
shorten the latency and increase the quantity of tumors
available for study [4,66]. In contrast to humans, it has
been reported that parous rats develop more breast
cancer than nulliparous rats [4]. Holtzman and colleagues
showed no differences in mammary adenocarcinoma risk
in a 10-month period after exposure in virgin, pregnant,
lactating and postlactating Sprague–Dawley rats [68]. A
similar-sized experiment but involving lifetime follow-up
found comparably increased risk of radiation-associated
mammary cancer for WAG/Rij rats exposed between ages
8 and 36 weeks, although none for rats exposed at the
‘postmenopausal’ age of 64 weeks [69].
Inano and colleagues [70] included animals exposed in
utero as well and found that, after 1 year of follow-up,
pregnant and lactating Wistar-MS rats were more
susceptible to radiation-associated mammary fibro-
adenoma and adenocarcinoma (compared with age-
matched non-exposed animals) than virgin or unborn rats
[70]. However, because the youngest at exposure were
followed up until a much younger adult age, it is possible
that they developed more breast tumors after the study
cut-off date. Because studies of cancers induced by
chemical agents showed that young virgin rats were more
susceptible than older rats [4], the authors proposed that
the carcinogenic impact of chemicals and radiation in rats
might involve different types of mammary stem cell [70].
Russo and Russo also proposed that the types and
behaviors of mammary neoplasms induced by different
carcinogens depend strongly on the particular structure
that is directly affected by the carcinogen. This is based
on observations that malignant tumors usually arise from
undifferentiated structures whereas benign lesions arise
mostly from more differentiated parts of the mammary
gland [4].
Another model of mammary gland carcinogenesis has
been proposed by Nandi’s group, in which the key
determinant is not the status of the breast cells, but rather
the hormonal milieu at the time of carcinogen exposure
[71]. Shimada and colleagues [72] proposed that
prepubertal rats are more sensitive to radiation-associated
cell killing than older animals because of a relative lack of
DNA repair before puberty. In contrast, one of the only
studies that included rats (Sprague–Daley) exposed
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before puberty showed less adenocarcinoma than those
exposed at later ages (42–225 days) [73].
Dogs are prone to mammary tumors but have not been
studied as much as rodents because of their longer
lifespan [74]. One large experiment, involving lifelong
follow-up of 672 female beagles exposed to various
radiation doses at different times in the prenatal, perinatal
and postnatal periods [74] showed no overall excess of
lifetime breast cancer mortality although there was
increased risk of non-fatal breast cancer in the subgroup
exposed to radiation in the perinatal period [75].
In summary we have abundant evidence from human
studies to support the assertion that females exposed
before age 10 years are at high risk of radiation-
associated breast cancer, and thus there are other factors
beside proliferative activity in the breast at the time of
exposure that determine susceptibility to radiation-
associated malignancies. Data on pregnancy-related
exposures (for both the female fetus and the mother) are
too sparse for meaningful conclusions. Some, but not all,
animal studies show variation in susceptibility to radiation-
associated mammary tumors by exposure age, breast
tissue status, and hormonal factors. Unfortunately, owing
to interspecies and intraspecies variability and the obvious
complexity of mammary carcinogenesis these data do not
provide a unified model to explain variation in human
susceptibility to radiation-associated mammary cancer.
Attained age (age at risk)
In epidemiological follow-up studies, attained age, or age
at observation for risk, is used to describe the period in
the life of a subject starting with radiation exposure and
ending with cancer occurrence, death, or the end of an
epidemiological follow-up study. In other words, the life of
each subject in a radiation-exposed cohort can be
represented by a timeline expressed in attained age, with
tick marks at the age of cancer diagnosis, age at death, or
age at the end of the follow-up for the study (for example
31 December 2003). This information can then be used to
calculate the risk of radiation-associated cancer at a
certain age or to adjust for attained age in the cohort.
Recently published analyses of radiation-related risk of all
solid cancers as a group show convincingly that the ERR
declines with increasing attained age [76]. However, the
effect of attained age on radiation-related breast cancer
risk is difficult to separate from that of age at exposure,
even in a population such as the atomic bomb survivors
for which exposure was to a general population of all ages
and follow-up has been of long duration. For example, the
correlation between age at exposure and age at diagnosis
was 0.7 for breast cancers diagnosed in the LSS
population between 1950 and 1990 [43]. Interestingly, in
the LSS, it turned out that the only significant effect of
attained age was explained by a high risk of early-onset
(before age 35 years) breast cancer in a subgroup of
women, whereas the relative risk remained fairly constant
for women older than 35 years at follow-up [43] (see also
the subsection ‘Genetic factors’ below). This effect was
independent of the strong modification of the dose
response by exposure age [43]. In a pooled analysis [45]
the EAR increased with advancing attained age, which is
consistent with the strong increase in background risk of
breast cancer with increasing age.
Reproductive history
Aside from the effects of age at exposure and attained age
as readily available surrogates for biological processes,
the effect of known reproductive risk factors has also been
studied more directly. Unfortunately, only a few
epidemiological studies collected the necessary
information and were large enough to address these
questions with sufficient statistical power. The most
comprehensive analysis so far is based on a nested case-
control study of 196 breast cancer patients and 566
matched controls among Japanese atomic bomb
survivors. As expected, early first birth, multiple births and
long cumulative lactation history had a protective effect
not only against baseline breast cancer but also against
radiation-associated breast cancer in this population, in
the sense that the dose-specific excess rate was reduced
at least as much as the baseline rate [77]. The protective
effect of early age at first birth held for women who were
parous at the time of exposure and for women who
completed a first pregnancy after radiation exposure,
suggesting that an early first pregnancy may protect
against the carcinogenic effects of radiation exposure on
the breast regardless of whether the exposure occurred
before or after the pregnancy [77]. This finding is
supported by results from an experimental rat model system
for radiation-associated mammary carcinogenesis [7].
Boice and Stone [65], in a hypothesis-generating report
based on small numbers, reported higher radiation-related
breast cancer risks in nulliparous versus parous tubercu-
losis patients, all exposed to multiple fluoroscopies. The
Rochester post-partum mastitis study showed no evidence
of deviation from the additive interaction model for age at
FFTP and radiation dose; the role of parity in itself could
not be evaluated because all women were parous and
lactating by definition [78]. A study of breast cancer risk
among more than 17,000 female infants treated with
various types of radiotherapy for skin hemangioma (67%
in head, neck, or thorax) also found no effect modification
by parity or age at first birth [79]. Despite the long period
between date of treatment and date at the end of the
study (45 years average, up to 76 years) this study had a
high rate of completeness for breast cancer ascertainment
because of linkage with the nationwide cancer registries in
Sweden and a good number of breast cancer cases
available for analysis (n = 245).
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Recently, two partly overlapping studies evaluated dose
response and its modifiers in a nested case-control study
of second breast cancer among HL survivors exposed to
very high radiation doses [41,46]. A strong reduction in
risk of radiation-associated breast cancer was seen for
women who had premature menopause due to
chemotherapy or ovarian radiation exposure, as had been
suggested previously [38,80]. In summary, reproductive
factors seem to be important in determining the risk of
radiation-related breast cancer, with suggestive evidence
for a reduced risk among multiparous women, or women
who had an early FFTP or very early menopause.
Benign breast disease
Motivated by earlier work [78], two recent reports
addressed the role of BBD. A pooled analysis of eight
radiation-exposed cohorts showed that women with BBD
had the highest excess rates of breast cancer after
radiation therapy for those disorders; this effect was most
pronounced among young women with BBD [45]. This
observation might be partly related to heightened
radiosensitivity in young women with BBD but might also
be due to the underlying association of BBD and breast
cancer. Although post-partum mastitis, an inflammation of
the breast after pregnancy belongs, strictly speaking, to a
different class of breast disorders, women who were
irradiated to treat post-partum mastitis also showed a
different pattern of radiation-associated risk than was
observed in the other, non-BBD radiation-exposed
cohorts of women [45]. Others reported increased breast
cancer risk in a case-control study of young women (less
than 40 years) exposed to diagnostic radiation before age
20 years, but the risk was observed only among women
who also reported a history of BBD [81]. However, these
results are based on self-reported X-ray exposures rather
than on medically verified exposures and/or
reconstructed estimates of the radiation dose that was
absorbed in the breast.
Family history
The variable ‘family history of breast and/or ovarian cancer’
did not act as an effect modifier in the mastitis series [78].
The question could not be evaluated in atomic bomb
survivors because of suspected poor knowledge and/or
reporting of this information [77]. In a case-control study
among young women, medical radiation exposures before
age 20 years were associated with a slightly increased
risk of breast cancer regardless of family history of breast
or ovarian cancer, whereas increased risk after adult
exposures was observed only among those with a positive
family history [81]. However, only self-reported information
on X-ray exposures and family history of disease was
available. It should be kept in mind that ‘family history’ is
only a very crude measure of possible genetic effects in
that it represents a mixture of background risk of breast
cancer (which is high in Western countries), shared
environmental influences, genetic factors, and combina-
tions of environmental and genetic factors [82].
Genetic factors
The occurrence of early-onset breast cancer is another
surrogate measure for possible genetic and other factors.
Both the atomic bomb survivor data [43,63] and a Dutch
cohort study of HL survivors [80] showed a highly
increased risk of early-onset breast cancer among women
who were exposed to radiation in childhood or
adolescence. These findings were later replicated in an
international collaborative study of 14,000 female HL
survivors, including the original Dutch cohort. When the
survivors were classified by age at HL diagnosis and
attained age, the highest risk was seen for early-onset
breast cancer (diagnosed before age 40 years) among the
group of women treated for HL before age 20 years
(relative risk 33.2) [83]. Despite speculation about a
genetically susceptible subgroup [84], responsible genes
have not been identified.
There are, however, several potential candidates. Genes
affecting DNA repair processes have been implicated in
particular because DNA is a direct target for ionizing
radiation in the cell. Various types of damage caused by
ionizing radiation include, for example, damage to single
bases, single-strand breaks, double-strand breaks (DSBs)
and multiply-damaged sites. Single-base and single-strand
damage are not specific to radiation and can be repaired
rapidly and with high fidelity, by using the non-affected
strand as template to fill the gaps with complementary
bases. In contrast, DSBs are caused by few other
carcinogens. It has been hypothesized that the linear
dose–response relationship for relatively low radiation
doses, as found for breast cancer, reflects the linear
association between radiation dose and DSBs [85]. If left
unrepaired, DSBs will in most cases lead to cell death
through either apoptosis or mitotic cell death due to loss
of genetic material [86]. Alternatively, effective DNA repair
will solve the problem. Recent cell culture studies found
that DNA repair mechanisms are not activated in the
presence of DSBs induced at very low radiation doses
(about 1 mSv) [87]. This may be a protective mechanism,
avoiding possible misrepair. However, if repaired incorrectly,
DSBs can lead to carcinogenesis through translocations,
inversions, or deletions of genetic material [86].
The principal mechanisms for repair of DSBs in
mammalian cells are homologous recombination and non-
homologous end joining (NHEJ). Homologous
recombination is an accurate process in which the
unaffected chromatid is used as template; homologous
recombination, however, is less frequently used than
NHEJ, an error-prone process of illegitimately linking the
broken pieces back together without reference to the
accurate base pairing. The resulting chromosomes are
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probably a major contributor to the first step in the
carcinogenic path of ionizing radiation. Each repair
process involves damage recognition, a pause in the cell
cycle to permit repair before the cell divides, and actual
repair [88]. The efficacy of DNA damage repair may be
influenced by genes encoding proteins involved in cell-
cycle control, as well as genes encoding proteins explicitly
involved in repair activities. As the full complexity of the
processes involved in DSBs is unfolding [88,89] it is
becoming clear that these are not entirely distinct
processes because some proteins, for example those
encoded by the genes ataxia telangiectasia mutated
(ATM), BRCA1, and BRCA2, might have a role in both
homologous recombination and NHEJ [89].
Research on the interplay of genes and radiation in the
etiology of breast cancer has focused on several different
aspects including (1) patients with very rare heritable
syndromes, characterized by radiosensitivity and high
cancer risk, (2) carriers of mutations in known breast
cancer susceptibility genes, and (3) genetic
polymorphisms, that is, increased occurrence of so-called
‘rare variants’ in the population in genes that have a role in
DNA repair. Each will be discussed briefly below.
Ataxia–telangiectasia (AT) is a very rare condition caused
by mutations in the ATM gene, which is involved in cell
cycle control and DNA damage recognition, in particular
DSBs. Patients with AT, who have two defective copies of
the gene, are at highly increased risk of lymphohemato-
poietic malignancies and other disorders at young ages.
Although cells of these patients are highly radiosensitive,
the risk of breast cancer in AT patients is not clear because
these patients often die young, before reaching the ages at
which most breast cancers in the general population
usually arise. Because AT is a recessive disorder, a
substantially larger proportion (1.4%) of the population
comprises so-called heterozygous carriers of an ATM
mutation in only one of the two copies of the gene [23,90].
The risk of breast cancer after radiation exposure in ATM
heterozygotes is unclear and has been subject to fierce
debate [91,92]. Early population-based studies found no
ATM mutations in breast cancer patients [91,92]. In
contrast, female family members of AT patients, in
particular mothers (who by definition have a defective
copy of the ATM gene), did have increased breast cancer
risk [93]. Also, cells of heterozygous carriers were
reported to have intermediate radiosensitivity between AT
patients and wild-type homozygotes, that is, subjects who
have two normal copies [91,92]. Because many different
types of ATM mutations have been identified so far, and
more probably remain to be discovered, it has been
suggested that ATM mutations involved with increased
risk of breast cancer among ATM heterozygotes might be
of a different type from the ATM mutations found in most
(although not all) AT patients [91,92]. Recently, Dutch
investigators used a highly selective group of breast
cancer patients with early-onset disease (less than 45 years
of age) and a high prevalence of bilateral disease, which
are both characteristics of possible genetic susceptibility
and found a high prevalence (9%) of ATM mutations,
including several different types [94]. A much larger series
that included 511 patients with bilateral disease in the
USA did not confirm these results [95].
Although there is some evidence that the ATM gene has a
role in breast cancer susceptibility and in radiosensitivity,
there as yet is no direct evidence for an increased risk of
radiation-associated breast cancer among ATM
heterozygotes [92,96]. However, sensitivity to radiation-
associated mammary ductal dysplasia (a precursor for
tumors) has been confirmed in mice heterozygous for AT
mutations [97]. Like AT, Nijmegen breakage syndrome is a
rare recessive genetic disorder characterized by increased
radiosensitivity and predisposition for lymphohemato-
poietic malignancies at young age [98]. Currently there is
no evidence that heterozygotes are at increased risk of
breast cancer [98,99].
Several other human genetic disorders are characterized
by high risks of cancer and potential defects in DNA repair
capacity, genomic maintenance, and cell-cycle control (for
example xeroderma pigmentosum, Bloom syndrome,
Fanconi anemia, retinoblastoma, Li–Fraumeni syndrome)
[100]. Retinoblastoma is a rare cancer of the retina that
arises in young children and can be either sporadic or
hereditary. Patients with the hereditary form of the disease
are born with one mutated retinoblastoma (RB) gene.
Evidence regarding breast cancer risk is scarce; three
available cohort studies reported on a total of 12 cases of
breast cancer only [101–103]. Further follow-up of these
relatively young cohorts might elucidate the risk of breast
cancer and the possible role of radiotherapy.
Metachronous second cancers of the colon and lung have
been reported in the radiotherapy field in a patient with
Li–Fraumeni syndrome who had radiotherapy for breast
cancer [104]. A recent Childhood Cancer Survivor Study
analysis showed that a family history of sarcoma (which is,
with breast cancer, one of the hallmarks of Li–Fraumeni
syndrome) was an independent risk factor for the
occurrence of a secondary breast cancer among survivors
of childhood cancer. However, there was no evidence that
a family history of sarcoma enhanced the already
increased risk of a secondary breast cancer after chest
radiotherapy for a childhood cancer [36]. A systematic
evaluation of radiation-related breast cancer in
Li–Fraumeni syndrome has not yet been possible.
An expert committee of the International Committee on
Radiological Protection concluded that the role of family
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cancer syndromes on population risk estimates was
probably very small, with the possible exception of
affected children and young adults exposed to therapeutic
radiation, among whom dose-reduction in high-dose
radiotherapy should be considered, within the limits of
therapeutic needs [100]. Importantly, the committee
recognized the relative paucity of data upon which to base
their conclusions, in particular the knowledge on the
identity, prevalence, and impact of weakly expressed
mutations that do not manifest as familial cancer [100].
The risk of breast cancer after radiation exposure among
carriers of mutations in the BRCA1 and BRCA2 genes
also is unclear. Although tumors deficient in BRCA1 and
BRCA2 show marked sensitivity to ionizing radiation and
drugs that produce DSBs [105], several cell-based
studies of BRCA1 and BRCA2 mutation carriers failed to
show increased radiosensitivity [106–108]. The low
frequency of all aforementioned mutations in the
population makes it challenging to study radiation-
associated breast cancer risk among carriers, and so far
no epidemiological data are available.
In contrast with these very rare, gene-specific mutations,
more common variations in genes (polymorphisms) might
cause more subtle variations in DNA repair capacity at the
population level, in particular when multiple genes from
one pathway are studied [109]. Although low-penetrance
DNA repair genes represent an area of active research,
currently available studies typically report main effects of
the DNA repair gene polymorphisms. It is challenging to
study the combined role of genes and radiation in the
etiology of breast cancer in humans because one needs a
large population exposed to a range of radiation doses to
ensure statistical power to detect such a gene–radiation
interaction, accurate estimates of radiation dose to the
breast, availability of blood samples or other biospecimen
types to perform genotyping on extracted DNA, and an
appropriate comparison group. Also, the genetic mutation
or polymorphism of interest is typically very rare, further
complicating matters. Thus, so far, few studies have
fulfilled all of these criteria. Efforts are underway, for
example, to assess the roles of polymorphisms in DNA
repair genes and low-dose chronic radiation exposure
among women enrolled in the US Radiologic Technologist
Cohort [110,111] and the roles of both polymorphic
variation in ATM and radiotherapy for the risk of
contralateral breast cancer among breast cancer survivors
in the Women’s Environmental Cancer and Radiation
Epidemiology (WECARE) study [96].
Conclusions
Ionizing radiation is an established breast cancer risk
factor, and the risk increases linearly with dose. Age at
exposure is a consistent modifier of the radiation-related
breast cancer risk, with the highest risk seen for girls
exposed before age 20 years and zero to minimal risk
detected for women exposed after the menopausal ages.
Sparse data suggest a high radiation risk among women
exposed while pregnant. A small number of studies
showed evidence that other etiologic factors for breast
cancer, namely age at first birth (before or after radiation
exposure), parity, and a history of benign breast disease,
influence the risk of a radiation-related breast cancer as
well. Although the role of genetic factors in radiation-
related breast cancer is of great interest, it is very
challenging to study; except for a likely role of the ATM
gene, so far few other genetic risk factors have been
established.
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